Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)‐inhibitors indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. The aim of this study was to investigate whether min...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Groenland, Stefanie L., Geel, Dieuwertje R., Janssen, Julie M., de Vries, Niels, Rosing, Hilde, Beijnen, Jos H., Burgers, Jacobus A., Smit, Egbert F., Huitema, Alwin D.R., Steeghs, Neeltje
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7891593/
https://ncbi.nlm.nih.gov/pubmed/32686074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1989
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados